Cushing Syndrome, Neoplasms
Conditions
Brief summary
The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.
Detailed description
The investigational medicinal product (IMP), relacorilant, and the non-investigational medicinal product (NIMP), dabigatran etexilate, will be used to evaluate the effect of relacorilant on the PK of the sensitive P-gp substrate, dabigatran etexilate in healthy participants. Participants will receive a single dose of dabigatran etexilate before and after administration of daily (QD) doses of relacorilant for 11 days. As all participants will receive the same treatments, the study will be open-label and no randomization is required.
Interventions
DRUGDabigatran Etexilate
Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
DRUGRelacorilant
Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
Sponsors
Corcept Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Must agree to use an adequate method of contraception * Healthy men or non-pregnant, non-lactating healthy women of non-childbearing potential * Body mass index (BMI) of 19.0 to 32.0 kg/m\^2 as measured at screening * Weight ≥50 kg at screening
Exclusion criteria
* Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients * Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. * Significant serious skin disease, including rash, food allergy, eczema, psoriasis, or urticaria * History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, bleeding disorder or abnormal bleeding, or clinically significant active bleeding, congenital or acquired clotting disorders, neurological or psychiatric disorder * History of esophagitis, gastritis, gastroesophageal reflux surgery, or significant trauma or surgery within 1 month of IMP/NIMP administration * Have poor venous access that limits phlebotomy * Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection * Clinically significant abnormal clinical chemistry, hematology or thrombocytopenia, coagulation or urinalysis * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results * Evidence of renal impairment at screening * Pregnant or lactating women * Women of childbearing potential. A woman is considered of childbearing potential unless she is permanently sterile or is postmenopausal * Participants who have received any IMP in a clinical research study within 5 half-lives or within 30 days prior to first dose. * Participants who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days before IMP/NIMP administration. * Participants who are currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months before IMP/NIMP administration, or 3 months for inhaled products * Participants who are taking, or have taken, heparin, vitamin K antagonists or anti-platelet agents within 1 month before IMP/NIMP administration * Participants who are taking, or have taken, selective serotonin re-uptake inhibitors, serotonin and norepinephrine re-uptake inhibitors within 3 months before IMP/NIMP administration * History of any drug or alcohol abuse in the past 2 years * A confirmed positive alcohol urine test at screening or admission * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * Positive drugs of abuse test result * Male participants with pregnant or lactating partners * Donation of blood within 2 months or donation of plasma within 7 days prior to first dose of study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Dabigatran When Administered With and Without Relacorilant | Up to Day 14 |
| Area Under the Curve from Time 0 to the Time of Last Measurable Concentration (AUC0-last) of Dabigatran When Administered With and Without Relacorilant | Up to Day 14 |
| Area Under the Curve from Time 0 Extrapolated to Infinity (AUC 0-inf) of Dabigatran When Administered With and Without Relacorilant | Up to Day 14 |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECG) Measurements | Up to Day 14 |
| Plasma Concentrations of Relacorilant | Up to Day 6 |
| Number of Participants with Clinically Significant Abnormalities in Laboratory Safety Tests (Clinical Chemistry, Hematology, Urinalysis) | Up to Day 14 |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 30 days post final dose |
| Number of Participants with Clinically Significant Abnormalities in Blood Pressure and Heart Rate | Up to Day 14 |
Countries
United States
Outcome results
None listed